Treatment of Diabetic Ketoacidosis: Continuing Long-Acting Insulin and Stopping Short-Acting Insulin

When a patient presents with diabetic ketoacidosis (DKA), it is important to provide prompt treatment. This involves fluid replacement with isotonic saline and an intravenous insulin infusion at 0.1 unit/kg per hour. While this takes place, the patient’s normal long-acting insulin should be continued, but their short-acting insulin should be stopped to avoid hypoglycemia.

In addition to insulin and fluid replacement, correction of electrolyte disturbance is essential. Serum potassium levels may be high on admission, but often fall quickly following treatment with insulin, resulting in hypokalemia. Potassium may need to be added to the replacement fluids, guided by the potassium levels. If the rate of potassium infusion is greater than 20 mmol/hour, cardiac monitoring is required.

Overall, the key to successful treatment of DKA is a careful balance of insulin, fluids, and electrolyte replacement. By continuing long-acting insulin and stopping short-acting insulin, healthcare providers can help ensure the best possible outcome for their patients.

Thyroid eye disease can be triggered by radioiodine therapy, as has been extensively recorded, but most patients will ultimately need to undergo thyroxine replacement.

Management of Graves’ Disease

Despite numerous attempts, there is no clear consensus on the best way to manage Graves’ disease. The available treatment options include anti-thyroid drugs (ATDs), radioiodine treatment, and surgery. In recent years, ATDs have become the most popular first-line therapy for Graves’ disease. This is particularly true for patients who have significant symptoms of thyrotoxicosis or those who are at a high risk of hyperthyroid complications, such as elderly patients or those with cardiovascular disease.

To control symptoms, propranolol is often used to block the adrenergic effects. NICE Clinical Knowledge Summaries recommend that patients with Graves’ disease be referred to secondary care for ongoing treatment. If a patient’s symptoms are not controlled with propranolol, carbimazole should be considered in primary care.

ATD therapy involves starting carbimazole at 40mg and gradually reducing it to maintain euthyroidism. This treatment is typically continued for 12-18 months. The major complication of carbimazole therapy is agranulocytosis. An alternative regime, known as block-and-replace, involves starting carbimazole at 40mg and adding thyroxine when the patient is euthyroid. This treatment typically lasts for 6-9 months. Patients following an ATD titration regime have been shown to suffer fewer side-effects than those on a block-and-replace regime.

Radioiodine treatment is often used in patients who relapse following ATD therapy or are resistant to primary ATD treatment. However, it is contraindicated in pregnancy (should be avoided for 4-6 months following treatment) and in patients under the age of 16. Thyroid eye disease is a relative contraindication, as it may worsen the condition. The proportion of patients who become hypothyroid depends on the dose given, but as a rule, the majority of patients will require thyroxine supplementation after 5 years.

Differential Diagnosis of Endocrine Disorders: Symptoms and Treatment Options

Hypothyroidism, adrenal insufficiency, Cushing syndrome, primary hypoparathyroidism, and secondary hypoparathyroidism are all endocrine disorders that can present with various symptoms. Hypothyroidism may cause cerebellar ataxia, myxoedema, and congestive cardiac failure, and is treated with replacement of thyroid hormone. Adrenal insufficiency may cause tiredness, weakness, and postural hypotension, among other symptoms. Cushing syndrome may present with central obesity, skin and muscle atrophy, and osteoporosis. Primary hypoparathyroidism may cause hypocalcaemia symptoms, while secondary hypoparathyroidism may also present with hypocalcaemia symptoms. Treatment options vary depending on the specific disorder.

If blood glucose targets are not achieved through diet and metformin in gestational diabetes, insulin should be added. Pregnant women with GDM should aim to keep their CBGs below specific levels, including fasting at 5.3mmol/L and 1 hour postprandial at 7.8 mmol/L or 2 hours postprandial at 6.4 mmol/L. If these targets are not met, insulin should be offered as an additional therapy. Gliclazide is not recommended, and the use of any sulphonylurea in GDM is an off-license indication. Gliptins are not recommended due to insufficient evidence of their safety in pregnancy. It is not appropriate to continue the same management or de-escalate treatment by stopping metformin if CBG readings are above target levels. Failure to achieve glycaemic control can result in serious risks to both mother and fetus, including pre-eclampsia, pre-term labour, stillbirth, and neonatal hypoglycaemia, even if fetal growth appears normal.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Different medications used to treat diabetes have varying mechanisms of action. Sulfonylureas like gliclazide stimulate insulin secretion from the pancreas, making them effective for type II diabetes but not for type I diabetes. However, they can cause hypoglycemia and should be used with caution when combined with other hypoglycemic medications. Biguanides like metformin increase glucose uptake and utilization while decreasing gluconeogenesis, making them a first-line treatment for type II diabetes. Glucosidase inhibitors like acarbose delay the digestion of starch and sucrose, but are not commonly used due to gastrointestinal side effects. DPP-4 inhibitors like sitagliptin increase insulin production and decrease hepatic glucose overproduction by inhibiting the action of DPP-4. Thiazolidinediones like pioglitazone increase insulin sensitivity in the liver, fat, and skeletal muscle, but their use is limited due to associated risks of heart failure, bladder cancer, and fractures.

Gliclazide is not the preferred initial treatment for type 2 diabetes. Due to the patient’s inability to tolerate metformin and a QRISK score of >10, there is now a higher likelihood of cardiovascular disease.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20mg as the first-line choice.

Subacute thyroiditis can be differentiated from Hashimoto’s thyroiditis as a cause of hypothyroidism by the presence of tenderness in the thyroid gland. The symptoms are indicative of hypothyroidism, which is confirmed by elevated TSH levels and low T4 levels in the thyroid function tests. The occurrence of a painful goitre points towards subacute thyroiditis as the most probable diagnosis. Graves’ disease, on the other hand, leads to hyperthyroidism and not hypothyroidism. Although Hashimoto’s thyroiditis can also cause hypothyroidism, it is typically painless. Riedel thyroiditis can cause hypothyroidism and may be painful, but it is less likely than subacute thyroiditis.

Understanding the Causes of Hypothyroidism

Hypothyroidism is a condition that affects a small percentage of women in the UK, with females being more susceptible than males. The most common cause of hypothyroidism is Hashimoto’s thyroiditis, an autoimmune disease that may be associated with other conditions such as IDDM, Addison’s or pernicious anaemia. Other causes of hypothyroidism include subacute thyroiditis, Riedel thyroiditis, thyroidectomy or radioiodine treatment, drug therapy, and dietary iodine deficiency. It is important to note that some of these causes may have an initial thyrotoxic phase.

In rare cases, hypothyroidism may also be caused by pituitary failure, which is known as secondary hypothyroidism. Additionally, there are certain conditions that may be associated with hypothyroidism, such as Down’s syndrome, Turner’s syndrome, and coeliac disease.

Medication Recommendations for a Patient with Diabetes and High Blood Pressure

Based on the patient’s HbA1c level, it is recommended to start first-line treatment with metformin. If the patient experiences poor tolerance or side-effects from metformin, gliclazide may be considered as a second-line option. Pioglitazone may also be used in conjunction with metformin if HbA1c is poorly controlled on monotherapy. However, the patient’s blood pressure is adequately controlled, so an additional antihypertensive is not necessary. Lastly, the patient’s LDL cholesterol level suggests adequate control, and therefore, there is no need to increase the dosage of atorvastatin.

To manage this patient with Addison’s disease who is experiencing an intercurrent illness, it is recommended to increase the glucocorticoid dose by double while keeping the fludrocortisone dose the same. The patient’s symptoms, including vomiting, confusion, fatigue, weight loss, and postural hypotension, suggest adrenal insufficiency. Blood tests reveal hyponatremia and hyperkalemia due to aldosterone deficiency. Aldosterone normally regulates sodium and potassium levels in the body, and its absence leads to sodium loss and potassium elevation. The prescribed steroid replacement regimen is appropriate for intercurrent illness, as it mimics the body’s natural response by increasing glucocorticoid secretion while maintaining mineralocorticoid secretion. The patient’s hydrocortisone dose has been doubled from 20mg to 40mg, while the fludrocortisone dose remains at 100mcg.

Addison’s disease is a condition that requires patients to undergo both glucocorticoid and mineralocorticoid replacement therapy. This treatment usually involves taking a combination of hydrocortisone and fludrocortisone. Hydrocortisone is typically given in 2 or 3 divided doses, with patients requiring 20-30 mg per day, mostly in the first half of the day. Patient education is crucial, and it is essential to emphasize the importance of not missing glucocorticoid doses. Additionally, patients should consider wearing MedicAlert bracelets and steroid cards, and they should be provided with hydrocortisone for injection with needles and syringes to treat an adrenal crisis.

During an intercurrent illness, it is crucial to manage the glucocorticoid dose properly. In simple terms, the glucocorticoid dose should be doubled, while the fludrocortisone dose should remain the same. The Addison’s Clinical Advisory Panel has produced guidelines that detail specific scenarios, and patients should refer to these guidelines for more information. It is essential to discuss how to adjust the glucocorticoid dose during an intercurrent illness with a healthcare professional. Proper management of Addison’s disease is crucial to ensure that patients can lead healthy and fulfilling lives.

Referral for Parathyroid Surgery in Primary Hyperparathyroidism

Primary hyperparathyroidism is a condition where the parathyroid glands produce too much parathyroid hormone (PTH), leading to high levels of calcium in the blood. The National Institute for Health and Care Excellence (NICE) recommends parathyroidectomy as the preferred treatment for most patients with diagnosed primary hyperparathyroidism due to its high cure rates and reduced risk of drug side effects.

Referral for parathyroid surgery is indicated for patients with confirmed hyperparathyroidism who have symptoms of hypercalcaemia, end-organ disease, or an albumin-adjusted serum calcium level of 2.85 mmol/l or above. This patient fits all three criteria and should be referred for parathyroid surgery.

Bisphosphonates and cinacalcet are only indicated when parathyroid surgery is not acceptable, patients are unfit for surgery, or have mild hypercalcaemia and symptoms. Laxatives and watchful waiting are not appropriate management options for hyperparathyroidism.

In conclusion, referral for parathyroid surgery is the most appropriate management option for patients with primary hyperparathyroidism who meet the criteria for surgery.

Endocrine Disorders: Congenital Adrenal Hyperplasia, Conn Syndrome, Addisonian Crisis, Cushing Syndrome, and Thyrotoxic Crisis

Endocrine disorders are conditions that affect the production and regulation of hormones in the body. Here are five different endocrine disorders and their characteristics:

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive conditions caused by mutations in the enzymes involved in the production of steroids and hormones from the adrenal glands. It can affect both men and women equally, and symptoms include ambiguous genitalia at birth for women and hyperpigmentation and penile enlargement for men. Treatment involves hormone replacement therapy.

Conn Syndrome is a condition associated with primary hyperaldosteronism, which presents with hypernatraemia and hypokalaemia. It is more commonly seen in adult patients, but there are cases reported in childhood.

Addisonian Crisis occurs due to glucocorticoid and mineralocorticoid deficiency, usually occurring in adulthood. It is a potentially fatal episode that presents with hyponatraemia, hyperkalaemia, hypoglycaemia, and hypercalcaemia. Urgent intravenous administration of glucocorticoids is necessary for management.

Cushing Syndrome is due to cortisol excess, either exogenous or endogenous, and is usually diagnosed in adulthood. Symptoms include weight gain, hypertension, oedema, hyperglycaemia, hypokalaemia, and pigmentation of the skin in the axillae and neck.

Thyrotoxic Crisis, also known as a thyroid storm, is a life-threatening condition associated with excessive production of thyroid hormones. It can be the first presentation of undiagnosed hyperthyroidism in neonates and children. Symptoms include tachycardia, hypertension, fever, poor feeding, weight loss, diarrhoea, nausea, vomiting, seizures, and coma. Prompt treatment is necessary to prevent acute congestive heart failure, shock, and death.

It is common for elderly patients who are unwell to have abnormal thyroid function tests, known as sick euthyroid. This is likely the case for the woman in question, as she has no history of thyroid disease and is not taking levothyroxine. It may be reasonable to consider starting levothyroxine, but it would be preferable to wait until her current illness has resolved. Discontinuing her antibiotics before completing her course is not appropriate, as they are unlikely to be causing the abnormal TFTs and she is currently asymptomatic. It is also unnecessary to perform a radio-isotope scan, as there is no suspicion of malignancy. Her thyroid function tests tomorrow are expected to be similar.

Understanding Sick Euthyroid Syndrome

Sick euthyroid syndrome, also known as non-thyroidal illness, is a condition where the levels of TSH, thyroxine, and T3 are low. However, it is important to note that in most cases, the TSH level is within the normal range, which is considered inappropriate given the low levels of thyroxine and T3. This condition is reversible and typically resolves upon recovery from the underlying systemic illness. As such, treatment is usually not necessary.

In summary, sick euthyroid syndrome is a condition where the thyroid hormone levels are low, but the TSH level is within the normal range. It is a reversible condition that typically resolves upon recovery from the underlying illness. No treatment is usually required for this condition.

Differentiating Adrenal Gland Disorders: Phaeochromocytoma, Conn Syndrome, Cushing Syndrome, PKD, and RAS

Adrenal gland disorders can present with similar symptoms, making it challenging to differentiate between them. However, understanding the unique features of each condition can aid in accurate diagnosis and appropriate management.

Phaeochromocytoma is a tumour of the adrenal gland that causes paroxysmal secretion of catecholamines, resulting in hypertension, headache, sweating, and anxiety. It is associated with the 10% rule, where 10% of cases are extramedullary, malignant, familial, and bilateral.

Conn syndrome, or primary aldosteronism, is characterised by hypertension, hypokalaemia, and metabolic alkalosis. The most common causes are aldosterone-producing adenomas and bilateral adrenal hyperplasia.

Cushing syndrome is caused by prolonged hypercortisolism and presents with centripetal obesity, secondary hypertension, glucose intolerance, proximal myopathy, and hirsutism. Sweating, palpitations, and elevated catecholamines are not typical of hypercortisolism.

Polycystic kidney disease (PKD) is associated with hypertension due to progressive kidney enlargement. It is a significant independent risk factor for progression to end-stage renal failure, but it does not cause elevated catecholamine levels.

Renal artery stenosis (RAS) is a major cause of renovascular hypertension, but it is not associated with elevated catecholamines or the symptoms described. Patients with RAS may also have a history of atherosclerosis, dyslipidaemia, smoking, and hypertension resistant to multiple antihypertensive medications.

In summary, understanding the unique features of adrenal gland disorders can aid in accurate diagnosis and appropriate management.

If a patient is experiencing metabolic ketoacidosis with normal or low glucose levels, alcohol consumption should be considered as a possible cause. This condition is characterized by partial respiratory compensation. While diabetic ketoacidosis could also be a potential cause, a serum glucose level of 3mmol/L makes it less likely. Therefore, the patient is more likely to be suffering from alcoholic ketoacidosis. It is important to note that a hyperosmolar hyperglycemic state would present with high serum glucose levels and normal ketone levels, while a diabetic hypoglycemic episode would not typically result in elevated ketone levels or metabolic acidosis.

Alcoholic ketoacidosis is a type of ketoacidosis that occurs in individuals who consume large amounts of alcohol regularly. This condition is not related to diabetes and is characterized by normal blood sugar levels. Alcoholics often suffer from malnutrition due to their irregular eating habits and may vomit the food they consume, leading to starvation. When the body becomes malnourished, it starts breaking down body fat, which produces ketones and leads to ketoacidosis.

The typical symptoms of alcoholic ketoacidosis include metabolic acidosis, elevated anion gap, elevated serum ketone levels, and normal or low glucose concentration. The most effective treatment for this condition is an infusion of saline and thiamine. Thiamine is essential to prevent the development of Wernicke encephalopathy or Korsakoff psychosis. Therefore, it is crucial to provide timely and appropriate treatment to individuals suffering from alcoholic ketoacidosis to prevent further complications.

Endocrine Disorders and Their Clinical Presentations

Acromegaly, Cushing’s syndrome, hyperprolactinaemia, hyperthyroidism, and multiple sclerosis are all endocrine disorders that can present with various clinical features. Acromegaly is caused by excess growth hormone secretion and can lead to enlarged hands, coarse facial features, and bitemporal hemianopia. Cushing’s syndrome may present with central obesity, muscle atrophy, and osteoporosis, but visual dysfunction is not typical. Hyperprolactinaemia can cause amenorrhoea or oligomenorrhoea, infertility, and galactorrhoea, but this presentation more closely fits with acromegaly. Hyperthyroidism may present with weight loss, tremor, and heat intolerance, but bitemporal hemianopia is not typical. Multiple sclerosis is a chronic inflammatory demyelination of the central nervous system and can present with various symptoms, but this patient’s presentation does not fit with features of multiple sclerosis.

Thyrotoxicosis is primarily caused by Graves’ disease in the UK, while the other conditions that can lead to thyrotoxicosis are relatively rare.

Understanding Thyrotoxicosis: Causes and Investigations

Thyrotoxicosis is a condition characterized by an overactive thyroid gland, resulting in an excess of thyroid hormones in the body. Graves’ disease is the most common cause, accounting for 50-60% of cases. Other causes include toxic nodular goitre, subacute thyroiditis, post-partum thyroiditis, Hashimoto’s thyroiditis, amiodarone therapy, and contrast administration. The latter is rare but can occur in elderly patients with pre-existing thyroid disease. Patients with existing thyrotoxicosis should not receive iodinated contrast medium as it can result in hyperthyroidism developing over 2-12 weeks due to a large iodine load to the thyroid.

Investigations for thyrotoxicosis include measuring TSH, which is typically low, and T4 and T3, which are elevated. Thyroid autoantibodies may also be tested. Isotope scanning may be done in some cases, but other investigations are not routinely performed. It is important to note that many causes of hypothyroidism may have an initial thyrotoxic phase, as shown in a Venn diagram. Understanding the causes and investigations of thyrotoxicosis is crucial for proper diagnosis and management of this condition.

Medical Conditions and Differential Diagnosis

Addisonian Crisis: A condition caused by adrenal insufficiency, often due to autoimmune disease, TB, metastases, or adrenal haemorrhage. Symptoms include vague complaints such as depression, anorexia, and GI upset, as well as tanned skin and pigmented palmar creases. Diagnosis is confirmed through a short ACTH stimulation test. Emergency treatment involves IV hydrocortisone and fluids, while long-term treatment involves oral cortisol and mineralocorticoid.

Other Differential Diagnoses: Meningococcal septicaemia, insulin overdose, paracetamol overdose, and salicylate overdose. However, the clinical features described in the scenario are not suggestive of these conditions.

Possible Causes of Hypertension, Hypercalcemia, and Low Magnesium in a Patient

One possible diagnosis for a patient with severe hypertension, hypercalcemia, and low magnesium is MEN 2a, also known as Sipple syndrome. This is because these symptoms can be explained by the presence of a phaeochromocytoma and hyperparathyroidism, which are both associated with MEN 2a.

Conn syndrome, which is characterized by asymptomatic hypertension and hypokalemia, is not the most likely diagnosis in this case since the patient is normokalemic and has high calcium levels. Phaeochromocytoma could explain the hypertension, but not the hypercalcemia and low magnesium.

MEN 1, also known as Wermer syndrome, is associated with hyperparathyroidism, pancreatic endocrine tumors, and pituitary tumors, but rarely with phaeochromocytoma. Wagenmann-Froboese syndrome, or MEN 2b, is associated with medullary thyroid carcinoma and phaeochromocytoma, but hyperparathyroidism is rarely present.

Therefore, based on the patient’s symptoms, MEN 2a or Sipple syndrome is the most likely diagnosis.

Fluid retention may be caused by pioglitazone.

Thiazolidinediones: A Class of Diabetes Medications

Thiazolidinediones are a type of medication used to treat type 2 diabetes. They work by activating the PPAR-gamma receptor, which reduces insulin resistance in the body. However, one medication in this class, rosiglitazone, was withdrawn in 2010 due to concerns about its cardiovascular side effects.

The PPAR-gamma receptor is a nuclear receptor found inside cells. It is naturally activated by free fatty acids and is involved in regulating the differentiation and function of adipocytes (fat cells).

While thiazolidinediones can be effective in treating diabetes, they can also have adverse effects. Patients may experience weight gain, liver impairment (which requires monitoring of liver function tests), and fluid retention. Thiazolidinediones are contraindicated in patients with heart failure due to the increased risk of fluid retention, especially if the patient is also taking insulin. Recent studies have also shown an increased risk of fractures and bladder cancer in patients taking pioglitazone, another medication in this class.

Urinary Metabolites as Diagnostic Markers for Adrenal Tumors and Disorders

The urinary excretion of certain metabolites can serve as diagnostic markers for various adrenal tumors and disorders. For instance, metanephrines, vanillylmandelic acid (VMA), and homovanillic acid (HVA) are the principal metabolic products of adrenaline and noradrenaline. Normal individuals excrete only minimal amounts of these substances in the urine. However, in phaeochromocytoma and neuroblastoma, urinary excretion of adrenaline and noradrenaline, and their metabolic products, increases intermittently.

Similarly, increased urinary excretion of the serotonin metabolite 5-hydroxyindoleacetic acid is seen in functioning carcinoids. Free urinary cortisol levels are elevated in Cushing syndrome, which is characterized by weight gain, fatty tissue deposits, moon face, buffalo hump, striae, thin skin, and acne. Urinary dehydroepiandrosterone excretion is often increased in congenital adrenal hyperplasia, while urinary pregnanetriol excretion is often increased in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.

It is important to note that elevated excretion of these compounds may also occur in other conditions such as coma, dehydration, extreme stress states, medication use, and ingestion of certain foods. Therefore, careful interpretation of urinary metabolite levels is necessary for accurate diagnosis of adrenal tumors and disorders.

Managing Type 1 Diabetes: NICE Guidelines

The management of type 1 diabetes is a complex process that involves the collaboration of various healthcare professionals. It is crucial to monitor the condition regularly as it can reduce life expectancy by 13 years and lead to micro and macrovascular complications. In 2015, NICE released guidelines on the diagnosis and management of type 1 diabetes, which provide valuable information for clinicians caring for patients with this condition.

One of the key recommendations is to monitor HbA1c levels every 3-6 months, with a target of 48 mmol/mol (6.5%) or lower for adults. However, other factors such as daily activities, comorbidities, and history of hypoglycemia should also be considered. Self-monitoring of blood glucose is also essential, with a minimum of four tests per day, including before meals and bedtime. Blood glucose targets should be between 5-7 mmol/l on waking and 4-7 mmol/l before meals at other times of the day.

NICE recommends multiple daily injection basal-bolus insulin regimens as the preferred choice for adults with type 1 diabetes, rather than twice-daily mixed insulin regimens. Rapid-acting insulin analogues should be used before meals instead of rapid-acting soluble human or animal insulins. Metformin may also be considered if the patient’s BMI is 25 kg/m² or higher.

In summary, managing type 1 diabetes requires a comprehensive approach that considers various factors. NICE guidelines provide a useful framework for clinicians to ensure optimal care for their patients with type 1 diabetes.

Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. However, mortality rates have decreased from 8% to under 1% in the past 20 years. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are ultimately converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and acetone-smelling breath. Diagnostic criteria include glucose levels above 13.8 mmol/l, pH below 7.30, serum bicarbonate below 18 mmol/l, anion gap above 10, and ketonaemia.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Most patients with DKA are depleted around 5-8 litres, and isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. DKA resolution is defined as pH above 7.3, blood ketones below 0.6 mmol/L, and bicarbonate above 15.0mmol/L. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral oedema. Children and young adults are particularly vulnerable to cerebral oedema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations.

Understanding the Causes of Hypercalcaemia

Hypercalcaemia is a medical condition characterized by high levels of calcium in the blood. In most cases, two conditions account for 90% of hypercalcaemia cases. The first is primary hyperparathyroidism, which is the most common cause in non-hospitalized patients. The second is malignancy, which is the most common cause in hospitalized patients. Malignancy-related hypercalcaemia may be due to various processes, including PTHrP from the tumor, bone metastases, and myeloma. For this reason, measuring parathyroid hormone levels is crucial when investigating patients with hypercalcaemia.

Other causes of hypercalcaemia include sarcoidosis, tuberculosis, histoplasmosis, vitamin D intoxication, acromegaly, thyrotoxicosis, milk-alkali syndrome, drugs such as thiazides and calcium-containing antacids, dehydration, Addison’s disease, and Paget’s disease of the bone. It is important to note that hypercalcaemia may occur with prolonged immobilization in patients with Paget’s disease of the bone, although this condition is usually normal.

In summary, hypercalcaemia can be caused by various medical conditions, with primary hyperparathyroidism and malignancy being the most common. Measuring parathyroid hormone levels is essential in investigating patients with hypercalcaemia. Other causes of hypercalcaemia include sarcoidosis, tuberculosis, histoplasmosis, vitamin D intoxication, acromegaly, thyrotoxicosis, milk-alkali syndrome, drugs, dehydration, Addison’s disease, and Paget’s disease of the bone.

When a patient has normal blood tests except for low thyroid function, which is indicated by low TSH and low free-T4, and presents with symptoms of hypothyroidism, it may be a case of secondary hypothyroidism caused by pituitary failure. This is a rare condition that requires imaging of the pituitary gland to rule out any anatomical or vascular causes, such as a tumor.

Understanding the Causes of Hypothyroidism

Hypothyroidism is a condition that affects a small percentage of women in the UK, with females being more susceptible than males. The most common cause of hypothyroidism is Hashimoto’s thyroiditis, an autoimmune disease that may be associated with other conditions such as IDDM, Addison’s or pernicious anaemia. Other causes of hypothyroidism include subacute thyroiditis, Riedel thyroiditis, thyroidectomy or radioiodine treatment, drug therapy, and dietary iodine deficiency. It is important to note that some of these causes may have an initial thyrotoxic phase.

In rare cases, hypothyroidism may also be caused by pituitary failure, which is known as secondary hypothyroidism. Additionally, there are certain conditions that may be associated with hypothyroidism, such as Down’s syndrome, Turner’s syndrome, and coeliac disease.

Complications of the hyperosmolar state, such as rhabdomyolysis, venous thromboembolism, lactic acidosis, hypertriglyceridemia, renal failure, stroke, and cerebral edema, contribute to the mortality of HONK. Identifying precipitants, such as a new diagnosis of type 2 diabetes, infection, high-dose steroids, myocardial infarction, vomiting, stroke, thromboembolism, and poor treatment compliance, is crucial.

Supportive care and slow metabolic resolution are the mainstays of HONK management. Patients with HONK often have a fluid deficit of over 8 liters, and caution should be exercised to avoid rapid fluid replacement, which can cause cerebral edema due to rapid osmolar shifts. In this scenario, fluid resuscitation should be the top priority, followed closely by initiating a sliding scale. Some experts recommend waiting for an hour before starting insulin to prevent rapid changes and pontine myelinolysis. However, the fluid alone can lower blood sugar levels, and some argue that administering insulin immediately can cause a precipitous drop in osmolality.

Understanding Hyperosmolar Hyperglycaemic State

Hyperosmolar hyperglycaemic state (HHS) is a medical emergency that can be life-threatening and difficult to manage. It is characterized by severe dehydration, electrolyte deficiencies, and osmotic diuresis resulting from hyperglycaemia. HHS typically affects elderly individuals with type 2 diabetes mellitus (T2DM).

The pathophysiology of HHS involves hyperglycaemia leading to increased serum osmolality, osmotic diuresis, and severe volume depletion. Precipitating factors include intercurrent illness, sedative drugs, and dementia. Clinical features of HHS include polyuria, polydipsia, signs of dehydration, lethargy, nausea, vomiting, altered level of consciousness, and focal neurological deficits.

Diagnosis of HHS is based on the presence of hypovolaemia, marked hyperglycaemia, significantly raised serum osmolarity, no significant hyperketonaemia, and no significant acidosis. Management of HHS involves fluid replacement with IV 0.9% sodium chloride solution, potassium monitoring, and insulin administration only if blood glucose stops falling while giving IV fluids. Patients with HHS are at risk of thrombosis due to hyperviscosity, and venous thromboembolism prophylaxis is recommended.

Complications of HHS include vascular complications such as myocardial infarction and stroke. It is important to recognize the clinical features of HHS and manage it promptly to prevent mortality.

Overall, HHS is a serious medical condition that requires urgent attention and management. Understanding its pathophysiology, clinical features, and management is crucial in providing appropriate care to patients with HHS.

The most probable diagnosis in this case is primary hyperparathyroidism, which is caused by parathyroid adenoma or hyperplasia. The typical biochemical markers are low phosphate and high serum calcium levels. However, the parathyroid hormone level may be high or inappropriately normal. On the other hand, secondary hyperparathyroidism is caused by chronic hypocalcemia, such as in chronic kidney disease, where serum calcium levels are low or normal, but parathyroid hormone levels are high. Tertiary hyperparathyroidism is a result of autonomous parathyroid production and usually occurs in patients with end-stage renal disease. Sarcoidosis and type 1 renal tubular acidosis are rare causes of hypercalcemia.

Understanding Primary Hyperparathyroidism

Primary hyperparathyroidism is a condition commonly seen in elderly females, characterized by an unquenchable thirst and an inappropriately normal or raised parathyroid hormone level. It is usually caused by a solitary adenoma, with hyperplasia, multiple adenoma, and carcinoma being less common causes. While around 80% of patients are asymptomatic, those who do experience symptoms may have polydipsia, polyuria, depression, anorexia, nausea, constipation, peptic ulceration, pancreatitis, bone pain/fracture, renal stones, and hypertension. Primary hyperparathyroidism is also associated with multiple endocrine neoplasia (MEN I and II).

To diagnose primary hyperparathyroidism, doctors may look for raised calcium levels and low phosphate levels, as well as perform a technetium-MIBI subtraction scan. A characteristic X-ray finding of hyperparathyroidism is the pepperpot skull. Treatment options include total parathyroidectomy, conservative management, and the use of calcimimetics like cinacalcet. Calcimimetics mimic the action of calcium on tissues by allosteric activation of the calcium-sensing receptor.

In summary, primary hyperparathyroidism is a condition that can be asymptomatic or present with a range of symptoms. It is most commonly caused by a solitary adenoma and is associated with multiple endocrine neoplasia. Diagnosis involves blood tests and imaging, while treatment options include surgery and medication.

Based on the presence of thyrotoxic symptoms, goitre, and anti-thyroid peroxidase antibodies, the likely diagnosis is

Graves’ Disease: Common Features and Unique Signs

Graves’ disease is the most frequent cause of thyrotoxicosis, which is commonly observed in women aged 30-50 years. The condition presents typical features of thyrotoxicosis, such as weight loss, palpitations, and heat intolerance. However, Graves’ disease also exhibits specific signs that are not present in other causes of thyrotoxicosis. These include eye signs, such as exophthalmos and ophthalmoplegia, as well as pretibial myxoedema and thyroid acropachy. The latter is a triad of digital clubbing, soft tissue swelling of the hands and feet, and periosteal new bone formation.

Autoantibodies are also present in Graves’ disease, including TSH receptor stimulating antibodies in 90% of patients and anti-thyroid peroxidase antibodies in 75% of patients. Thyroid scintigraphy can also aid in the diagnosis of Graves’ disease, as it shows diffuse, homogenous, and increased uptake of radioactive iodine.

Overall, Graves’ disease presents with both typical and unique features that distinguish it from other causes of thyrotoxicosis. Early diagnosis and treatment are crucial to prevent complications and improve outcomes for patients.

There is no need to take any action regarding his cholesterol as it is under control. Additionally, his blood pressure is also well managed. However, his HbA1c level is in the pre-diabetes range (42-47 mmol/mol) and requires further investigation. It is important to note that a HbA1c reading alone cannot rule out diabetes, and a fasting sample should be arranged for confirmation.

Type 2 diabetes mellitus can be diagnosed through a plasma glucose or HbA1c sample. The diagnostic criteria vary depending on whether the patient is experiencing symptoms or not. If the patient is symptomatic, a fasting glucose level of 7.0 mmol/l or higher or a random glucose level of 11.1 mmol/l or higher (or after a 75g oral glucose tolerance test) indicates diabetes. If the patient is asymptomatic, the same criteria apply but must be demonstrated on two separate occasions.

In 2011, the World Health Organization released supplementary guidance on the use of HbA1c for diagnosing diabetes. A HbA1c level of 48 mmol/mol (6.5%) or higher is diagnostic of diabetes mellitus. However, a HbA1c value of less than 48 mmol/mol (6.5%) does not exclude diabetes and may not be as sensitive as fasting samples for detecting diabetes. For patients without symptoms, the test must be repeated to confirm the diagnosis. It is important to note that increased red cell turnover can cause misleading HbA1c results.

There are certain conditions where HbA1c cannot be used for diagnosis, such as haemoglobinopathies, haemolytic anaemia, untreated iron deficiency anaemia, suspected gestational diabetes, children, HIV, chronic kidney disease, and people taking medication that may cause hyperglycaemia (such as corticosteroids).

Impaired fasting glucose (IFG) is defined as a fasting glucose level of 6.1 mmol/l or higher but less than 7.0 mmol/l. Impaired glucose tolerance (IGT) is defined as a fasting plasma glucose level less than 7.0 mmol/l and an OGTT 2-hour value of 7.8 mmol/l or higher but less than 11.1 mmol/l. People with IFG should be offered an oral glucose tolerance test to rule out a diagnosis of diabetes. A result below 11.1 mmol/l but above 7.8 mmol/l indicates that the person does not have diabetes but does have IGT.

Managing Hypothyroidism: Dosage, Monitoring, and Side-Effects

Hypothyroidism is a condition where the thyroid gland does not produce enough thyroid hormone. The main treatment for hypothyroidism is levothyroxine, a synthetic form of thyroid hormone. When managing hypothyroidism, it is important to consider the patient’s age, cardiac history, and initial starting dose. Elderly patients and those with ischaemic heart disease should start with a lower dose of 25mcg od, while other patients can start with 50-100mcg od. After a change in dosage, thyroid function tests should be checked after 8-12 weeks to ensure the therapeutic goal of normalising the thyroid stimulating hormone (TSH) level is achieved. The target TSH range is 0.5-2.5 mU/l.

Women with hypothyroidism who become pregnant should have their dose increased by at least 25-50 micrograms levothyroxine due to the increased demands of pregnancy. The TSH should be monitored carefully, aiming for a low-normal value. It is important to note that there is no evidence to support combination therapy with levothyroxine and liothyronine.

While levothyroxine is generally well-tolerated, there are some potential side-effects to be aware of. Over-treatment can lead to hyperthyroidism, while long-term use can reduce bone mineral density. In patients with cardiac disease, levothyroxine can worsen angina and lead to atrial fibrillation. It is also important to be aware of drug interactions, particularly with iron and calcium carbonate, which can reduce the absorption of levothyroxine. These medications should be given at least 4 hours apart.

In summary, managing hypothyroidism involves careful consideration of dosage, monitoring of TSH levels, and awareness of potential side-effects and drug interactions. With appropriate management, patients with hypothyroidism can achieve normal thyroid function and improve their overall health.

Osteopaenia and osteoporosis are associated with prolonged use of corticosteroids, not osteomalacia.

Understanding Corticosteroids and Their Side-Effects

Corticosteroids are commonly prescribed therapies used to replace or augment the natural activity of endogenous steroids. They can be administered systemically or locally, depending on the condition being treated. However, the usage of corticosteroids is limited due to their numerous side-effects, which are more common with prolonged and systemic therapy.

Glucocorticoid side-effects include impaired glucose regulation, increased appetite and weight gain, hirsutism, hyperlipidaemia, Cushing’s syndrome, moon face, buffalo hump, striae, osteoporosis, proximal myopathy, avascular necrosis of the femoral head, immunosuppression, increased susceptibility to severe infection, reactivation of tuberculosis, insomnia, mania, depression, psychosis, peptic ulceration, acute pancreatitis, glaucoma, cataracts, suppression of growth in children, intracranial hypertension, and neutrophilia.

On the other hand, mineralocorticoid side-effects include fluid retention and hypertension. It is important to note that patients on long-term steroids should have their doses doubled during intercurrent illness. Longer-term systemic corticosteroids suppress the natural production of endogenous steroids, so they should not be withdrawn abruptly as this may precipitate an Addisonian crisis. The British National Formulary suggests gradual withdrawal of systemic corticosteroids if patients have received more than 40mg prednisolone daily for more than one week, received more than three weeks of treatment, or recently received repeated courses.